Hemophilia Management

Introduction

Expert Interview

Stay Connected

Join the conversation

Hemophilia Quick Facts

In 2014 the National Hemophilia Program Coordinating Center (NHPCC), in collaboration with hemophilia treatment centers (HTCs), conducted a survey of 31 HTCs with established 340B programs. The number of patients estimated to be served by these HTCs was 10,000. The two levels of the analysis were:

  • The level of 340B program income used to support the delivery of direct patient services
  • The level of services that are generally not billable to third-party payers and typically considered not reimbursable


Findings of this analysis included:

  • Overall, >90% of care coordination and case management services are supported with 340B program income in the majority of HTCs; these services are typically not funded by third-party payers
  • Most centers fund >50% of the salary costs of non-physicians (i.e., nurses, physical therapists, etc.) with 340B program income
    • Nearly all (>90%) HTCs support social workers with 340B funding
    • Home and school visits are nearly fully supported with 340B funding

Trujillo M, Forsberg AD, Drake J, Cheng D, McLaughlin K, McKernan L. National Survey of the 340B Drug Pricing Program: Quantitative Evaluation of the Services Provided by the U.S. Hemophilia Treatment Centers. Presented at the World Federation of Hemophilia 2016 World Congress; July 24-28, 2016; Orlando, FL.

Click here to view the poster

Questionnaire

Q1: With which type of organization are you affiliated?

Q2: What best describes your primary role at this organization?

Q3: Approximately how many patients with hemophilia are currently being managed in your plan or practice setting?

Q4: Is clotting factor replacement product covered as a major medical or pharmacy benefit within your organization?

Advisory Board

Jennifer Maahs, RN, PNP, MSN
Nurse Practitioner
Indiana Hemophilia and Thrombosis Center

Vanita K. Pindolia, PharmD, BCPS
Vice President, Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System/Health Alliance Plan of Michigan

Steven W. Pipe, MD
Director, Division of Pediatric Hematology and Oncology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
University of Michigan

Marion Koerper, MD Professor Emerita on Recall
Department of Pediatric Hematology
School of Medicine University of California, San Francisco
(UCSF) School of Medicine
Medical Advisor
National Hemophilia Foundation

Diane J. Nugent, MD Chair, Hematology
Medical Director, Hematology and Blood and Donor Services
Division Chief, Hematology
Children’s Hospital of Orange County

Celynda G. Tadlock, PharmD, MBA
Vice President Pharmacy Business Development, Aetna
President, Coventry Prescription Management Serivces, Inc.